Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23980720 | 1.00 | LPL (0.36) | LPLLIPGEGFR | |
| SCHEMBL29739929 | 0.90 | LPL (0.33) | LPLLIPG | |
| SCHEMBL31478095 | 0.84 | LPL (0.38) | LPLLIPGEGFR | |
| SCHEMBL24804122 | 0.83 | SNCA (0.33) | — | |
| SCHEMBL24804126 | 0.83 | CSF1R (0.34) | — | |
| SCHEMBL1494645 | 0.80 | LPL (0.40) | LPLLIPG | |
| SCHEMBL14645675 | 0.79 | LPL (0.39) | LPLLIPG | |
| SCHEMBL29520129 | 0.79 | LPL (0.39) | LPLLIPG | |
| SCHEMBL1494631 | 0.78 | LPL (0.38) | LPLLIPG | |
| SCHEMBL28839065 | 0.76 | F2 (0.31) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551559-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | Accro Bioscience (HK) Limited (HK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4337648-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337649-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4143180-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | Bristol-Myers Squibb Company (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022241174-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022241172-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYK2, WEE2, WEE1 | LPL 4465/4885LIPG 4086/4885EGFR 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.